EMD Millipore, the life science business of Merck KGaA of Darmstadt, Germany, and Singulex, the developer and provider of Single Molecule Counting (SMC) technology for clinical diagnostics and scientific discovery, have entered into an agreement under which EMD Millipore will control and manage the Singulex Life Science Research business. Under the terms of the agreement, EMD Millipore will pay Singulex an upfront payment, royalties and additional payments based upon achievement of certain commercial milestones. EMD Millipore will have exclusive rights to further develop and commercialize the SMC technology for research applications worldwide.
The SMC technology is a novel, patented technology combining signal enhancement and background reduction coupled with low volume sampling to achieve ultra-high sensitivity protein detection.
“This agreement is further evidence of EMD Millipore’s commitment to bringing innovative technologies to our global life science customers,” said Udit Batra, president and chief executive officer, EMD Millipore. “The Erenna platform offers the advantage of unrivaled sensitivity and precision and will be a strong addition to our protein detection franchise.”
“We are pleased with this strategic agreement with EMD Millipore since it puts our technology into the best possible hands to optimize its commercial scale-up and market potential,” said Guido Baechler, president and chief executive officer, Singulex. “This deal enables us to leverage our immunoassay technology to create additional opportunities in our other diagnostic businesses, especially within the area of companion diagnostics.
